Get the Stockscreener App
12.92
0.62%
-0.08
Pre-market:
12.59
-0.33
-2.55%
Day One Biopharmaceuticals Inc stock is currently priced at $12.92, with a 24-hour trading volume of 662.38K.
It has seen a -0.62% decreased in the last 24 hours and a -19.50% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $12.97 pivot point. If it approaches the $12.71 support level, significant changes may occur.
Previous Close:
$13.00
Open:
$12.97
24h Volume:
662.38K
Market Cap:
$1.13B
Revenue:
-
Net Income/Loss:
$-188.92M
P/E Ratio:
-5.6174
EPS:
-2.3
Net Cash Flow:
$-150.08M
1W Performance:
+0.31%
1M Performance:
-19.50%
6M Performance:
-8.82%
1Y Performance:
-5.35%
1D Range:
$12.68
$13.07
52W Range:
$9.67
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Name
Day One Biopharmaceuticals Inc
Sector
Industry
Phone
650 484 0899
Address
395 Oyster Point Boulevard, Suite 217, South San Francisco
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-08-23 | Initiated | CapitalOne | Overweight |
| Feb-03-23 | Initiated | Oppenheimer | Perform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Dec-05-22 | Initiated | Goldman | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
View All
Day One Biopharmaceuticals Inc Stock (DAWN) Latest News
Day One Biopharmaceuticals Inc [DAWN] HEAD OF R&D makes an insider purchase of 30000 shares worth 0.38 ... - Knox Daily
Knox Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by PFM Health Sciences LP - MarketBeat
MarketBeat
Biotech Stocks: The Top 5 To Watch As Shares Broadly Struggle - Investor's Business Daily
Investor's Business Daily
Day One Biopharmaceuticals Inc (DAWN) expanding its growth trajectory ahead – Sete News - SETE News
SETE News
Day One Biopharmaceuticals Updates FIREFLY-2 Trial Strategy - TipRanks.com - TipRanks
TipRanks
Day One Biopharmaceuticals Updates FIREFLY-2 Trial Strategy - TipRanks.com - TipRanks
TipRanks
Day One Biopharmaceuticals Inc Stock (DAWN) Financials Data
Day One Biopharmaceuticals Inc (DAWN) Net Income 2024
DAWN net income (TTM) was -$188.92 million for the quarter ending December 31, 2023, a -32.87% decrease year-over-year.
Day One Biopharmaceuticals Inc (DAWN) Cash Flow 2024
DAWN recorded a free cash flow (TTM) of -$150.08 million for the quarter ending December 31, 2023, a -36.56% decrease year-over-year.
Day One Biopharmaceuticals Inc (DAWN) Earnings per Share 2024
DAWN earnings per share (TTM) was -$2.38 for the quarter ending December 31, 2023, a -9.68% decline year-over-year.
Day One Biopharmaceuticals Inc Stock (DAWN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
May 16 '24 |
Sale |
16.08 |
7,873 |
126,588 |
654,728 |
| Dubow Adam | GENERAL COUNSEL |
May 16 '24 |
Sale |
16.08 |
3,253 |
52,304 |
21,731 |
| York Charles N II | COO, CFO AND SECRETARY |
May 16 '24 |
Sale |
16.08 |
2,675 |
43,011 |
224,868 |
| Blackman Samuel C. | HEAD OF R&D |
May 16 '24 |
Sale |
16.08 |
2,267 |
36,450 |
1,171,081 |
| Blackman Samuel C. | HEAD OF R&D |
May 10 '24 |
Sale |
16.37 |
10,000 |
163,743 |
1,164,662 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
May 03 '24 |
Sale |
17.85 |
9,154 |
163,417 |
642,602 |
| York Charles N II | COO, CFO AND SECRETARY |
May 03 '24 |
Sale |
17.85 |
8,078 |
144,214 |
217,293 |
| York Charles N II | COO, CFO AND SECRETARY |
May 02 '24 |
Sale |
17.90 |
200 |
3,579 |
225,371 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
May 02 '24 |
Sale |
17.94 |
6 |
108 |
651,756 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
May 01 '24 |
Sale |
17.88 |
70,051 |
1,252,183 |
651,762 |
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
0.37%
0.64%
Cap:
|
Volume (24h):